Management of Androgenetic Alopecia in Men in 2025: A Focused Review

Authors

  • Hanieh Zargham, MD, FRCPC Department of Dermatology and Skin Science, University of British Columbia, Vancouver

DOI:

https://doi.org/10.58931/cdt.2025.61137

Abstract

Androgenetic alopecia (AGA) affects a significant portion of the male population, with studies estimating that approximately 50% of men will experience some degree of AGA by the age of 50. This condition can lead to significant psychological distress and a reduced quality of life.

Recent advancements in understanding the multifactorial etiology of AGA have led to the development of new treatment strategies. This review provides an overview of the currently available treatments for AGA in men.

Author Biography

Hanieh Zargham, MD, FRCPC, Department of Dermatology and Skin Science, University of British Columbia, Vancouver

Dr. Zargham is a dermatologist practising in Vancouver. She graduated from McGill University and completed an additional 6 months of cosmetic training in Spain, South Korea, and Calgary. In addition to her community practice, she also serves as a clinical instructor with the Department of Dermatology and Skin Science at the University of British Columbia, where she runs a monthly skin cancer screening clinic for renal transplant patients.

References

Salman KE, Altunay IK, Kucukunal NA, Cerman AA. Frequency, severity and related factors of androgenetic alopecia in dermatology outpatient clinic: hospital-based cross-sectional study in Turkey. An Bras Dermatol. 2017;92(1):35–40. doi:10.1590/abd1806-4841.20175241.

Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999;41(5):717–21. doi:10.1016/s0190-9622(99)70006-x.

Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385. doi:10.1067/mjd.2002.124088.

Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541–553. doi:10.1016/j.jaad.2003.06.014.

Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126–1134.e2. doi:10.1016/j.jaad.2010.09.724.

Ghonemy S, Alarawi A, Bessar H. Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. J Dermatolog Treat. 2021;32(2):236–241. doi:10.1080/09546634.2019.1654070.

Piepkorn MW, Weidner M. Comparable efficacy of 2% minoxidil gel and solution formulations in the treatment of male pattern alopecia. J Am Acad Dermatol. 1988;18(5):1059–1062. doi:10.1016/s0190-9622(88)70105-x.

Piraccini BM, Blume‐Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286–294. doi:10.1111/jdv.17738.

Shin HS, Won CH, Lee SH, Kwon OS, Kim KH, Eun HC. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss. Am J Clin Dermatol. 2007;8(5):285–290. doi:10.2165/00128071-200708050-00003.

Berger RS, Fu JL, Smiles KA, Turner CB, Schnell BM, Werchowski KM, et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003;149(2):354–362. doi:10.1046/j.1365-2133.2003.05435.x.

Bharadwaj AV, Mendiratta V, Rehan HS, Tripathi S. Comparative efficacy of topical finasteride (0.25%) in combination with minoxidil (5%) against 5% minoxidil or 0.25% finasteride alone in male androgenetic alopecia: a pilot, randomized open-label study. Int J Trichology. 2023;15(2):56-62. doi: 10.4103/ijt.ijt_72_22.

Fields JR, Vonu PM, Monir RL, Schoch JJ. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Dermatologic Therapy. 2020;33:e13202. doi:10.1111/dth.13202.

Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29(8):489–498. doi:10.1111/j.1346-8138.2002.tb00314.x.

Goodwin Cartwright BM, Wang M, Rodriguez P, Stewart S, Worsham CM, et al. Changes in minoxidil prescribing after media attention about oral use for hair loss. JAMA Netw Open. 2023;6(5):e2312477. doi:10.1001/jamanetworkopen.2023.12477.

Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(6):600–605. doi:10.1001/jamadermatol.2024.0284.

Kincaid CM, Sharma AN, Sargent B, Gradus-Pizlo I, Dineen EH, Mesinkovska NA. Evaluation of pericardial effusions in alopecia patients on low-dose oral minoxidil therapy. J Drugs Dermatol. 2024;23(9):725-728. doi: 10.36849/JDD.8029.

Bokhari L, Jones LN, Sinclair RD. Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial. J Eur Acad Dermatol Venereol. 2022;36(1):e62-e66. doi: 10.1111/jdv.17623.

Sanabria B, Miot HA, Sinclair R, Chaves C, Müller Ramos P. Sublingual minoxidil 5 mg versus oral minoxidil 5 mg for male androgenetic alopecia: a double-blind randomized clinical trial. J Eur Acad Dermatol Venereol. Published online December 17, 2024. doi: 10.1111/jdv.20508.

Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatolog Treat. 2022;33(7):2946-2962. doi: 10.1080/09546634.2022.2109567.

Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019;14:399-406. doi: 10.2147/CIA.S192435.

Traish AM. Health risks associated with long-term finasteride and dutasteride use: it’s time to sound the alarm. World J Mens Health. 2020;38(3):323-337. doi: 10.5534/wjmh.200012.

Zhang X, Ji Y, Zhou M, Zhou X, Xie Y, Zeng X, et al. Platelet-rich plasma for androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. J Cutan Med Surg. 2023;27(5):504-508. doi: 10.1177/12034754231191461.

Singh SK, Kumar V, Rai T. Comparison of efficacy of platelet-rich plasma therapy with or without topical 5% minoxidil in male-type baldness: a randomized, double-blind placebo control trial. Indian J Dermatol Venereol Leprol. 2020;86(2):150-157. doi: 10.4103/ijdvl.IJDVL_589_18.

Saceda-Corralo D, Moustafa F, Moreno-Arrones Ó, Jaén-Olasolo P, Vañó-Galván S, Camacho F. Mesotherapy with dutasteride for androgenetic alopecia: a retrospective study in real clinical practice. J Drugs Dermatol. 2022;21(7):742-747. doi: 10.36849/JDD.6610.

Sobhy N, Aly H, El Shafee A, El Deeb M. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatol Online. 2013;4(1):40-45. doi: 10.7241/ourd.20131.08

Downloads

Published

2025-03-07

How to Cite

1.
Zargham H. Management of Androgenetic Alopecia in Men in 2025: A Focused Review. Can Dermatol Today [Internet]. 2025 Mar. 7 [cited 2025 Mar. 12];6(1):36–41. Available from: https://canadiandermatologytoday.com/article/view/6-1-Zargham

Issue

Volume 6, Issue 1, Spring 2025

Section

Articles